Table 1.

Clinical characteristics of patients and comparison of clinical and laboratory results before and after dornase alfa therapy

	Case 1	Case 2	Case 3
Gender	M	F	F
Age (years)	64	33	27
PCR	Positive	Positive	Positive
Comorbidity	Diabetes mellitus	Breast cancer	Critical
Disease presentation and course
Interval between admission and dornase alfa (days)	8	2	11
Treatments	H, F	H, F	H, F
Clinical characteristics
Body temperature (°C)
Before dornase alfa	36.3	38.3	37
Day 1 post dornase alfa	37.1	37.3	37.4
Day 2 post dornase alfa	36.7	37.2	36.6
Day 3 post dornase alfa	36.3	36	36.4
Dyspnoea
Before dornase alfa	Yes	Yes	Yes
Day 1 post dornase alfa	No	No	Yes
Day 2 post dornase alfa	No	No	No
Day 3 post dornase alfa	No	No	No
Coughing
Before dornase alfa	Yes	Yes	Yes
Day 1 post dornase alfa	Yes	Yes	Yes
Day 2 post dornase alfa	No	Yes	No
Day 3 post dornase alfa	No	No	No
Respiratory rate
Before dornase alfa	20	19	20
Day 1 post dornase alfa	18	19	20
Day 2 post dornase alfa	18	19	20
Day 3 post dornase alfa	18	18	18
Spo2
Before dornase alfa	95	96 (with oxygen)	91 (with oxygen)
Day 1 post dornase alfa	97	96	95 (with oxygen)
Day 2 post dornase alfa	97	96	97 (with oxygen)
Day 3 post dornase alfa	97	97	99 (with oxygen)
C-reactive protein (mg/L)
Before dornase alfa	9.1	5.6	16.4
Day 1 post dornase alfa	9.1	2.9	12.4
Day 2 post dornase alfa	7.3	1.9	11.9
Day 3 post dornase alfa	5.9	1.3	6.1
Procalcitonin (ng/mL)
Before dornase alfa	0.12	0.01	0.01
Day 1 post dornase alfa	0.12	0.01	0.03
Day 2 post dornase alfa	0.11	0.01	0.03
Day 3 post dornase alfa	0.06	0.01	0.01

Abbreviations: Spo₂, peripheral capillary oxygen saturation; H, hydroxychloroquine; F, favipiravir.